Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

LincoMed 300

This page contains information on LincoMed 300 for veterinary use.
The information provided typically includes the following:
  • LincoMed 300 Indications
  • Warnings and cautions for LincoMed 300
  • Direction and dosage information for LincoMed 300

LincoMed 300

This treatment applies to the following species:
Manufacturer: Bimeda

lincomycin injection, USP

Swine Antibiotic

ANADA 200-368, Approved by FDA

For use in swine weighing 300 pounds or more.

For Intramuscular Use in Swine Only

LincoMed® 300 contains lincomycin hydrochloride, an antibiotic produced by Streptomyces lincolnensis var. lincolnensis which is chemically distinct from all other clinically available antibiotics and is a white crystalline solid.


LincoMed® 300 is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. This includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, Erysipelothrix and Mycoplasma spp.

It is also indicated for the treatment of mycoplasma pneumonia.


As with all drugs, use of LincoMed® 300 is contraindicated in animals previously found to be hypersensitive to the drug.

Residue Warning: Swine intended for human consumption should not be slaughtered within 48 hours of latest treatment.

Human Warnings: Not for human use. Keep out of reach of children.

LincoMed 300 Caution

If no improvement is noted within 48 hours, consult a veterinarian.

Adverse Reactions

The intramuscular administration to swine may cause a transient diarrhea or loose stools. Although this effect has rarely been reported, one must be alert to the possibility that it may occur. Should this occur, it is important that the necessary steps be taken to prevent the effects of dehydration.

Dosage and Administration

For arthritis or mycoplasma pneumonia - 5 mg/lb body weight intramuscularly once daily for three to seven days as needed. One mL per 60 lb body weight will provide 5 mg/lb.

For optimal results, initiate treatment as soon as possible.

As with any multi-dose vial, practice aseptic techniques in withdrawing each dose. Adequately clean and disinfect the vial closure prior to entry with a sterile needle and syringe. No vial closure should be entered more than 20 times.

Each mL contains:

Lincomycin hydrochloride equivalent to lincomycin 300 mg; also benzyl alcohol 9.45 mg added as preservative.

How Supplied

100 mL multiple dose vials.

Store at controlled room temperature 20° to 25° C (68° to 77° F) [see USP]. KEEP FROM FREEZING.

For Intramuscular Use in Swine.

Restricted Drug (California) - Use Only as Directed. For Use in Animals Only.

Manufactured by: Bimeda-MTC Animal Health Inc., Cambridge, Ontario, Canada N3C 2W4

Manufactured for: Bimeda, Inc., Le Sueur, MN 56058

Bimeda, Inc. and Bimeda-MTC Animal Health Inc. are Divisions of Cross Vetpharm Group Ltd.

LincoMed is a Registered Trademark of Bimeda, Inc.


Product No.


100 mL (3.3 fl oz)



NAC No.: 13990851

Div. Cross Vetpharm Group, Ltd.

Telephone:   630-928-0361
Fax:   630-928-0362
Every effort has been made to ensure the accuracy of the LincoMed 300 information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2018 North American Compendiums. Updated: 2018-04-26